James Brugarolas
@JBrugarolas
Director Kidney Cancer Program at UT Southwestern Medical Center (http://www.utsouthwestern.edu/kidneycancer) Views my own/ RT not endorsements
Dr. @JBrugarolas of @UTSWMedCenter talks about his journey to becoming a #kidneycancer specialist in a new interview, highlighting key breakthroughs, his lab’s role in developing HIF-2 inhibitors, and his ongoing work to improve patient outcomes: buff.ly/8Sv3Osm
An Amazing Journey From VEGF to HIF-2 Targeting Drugs @KCPUTSW @kaelin_lab @utswcancer guoncologynow.com/post/from-vegf…
Congratulations, a great start! @KCPUTSW
My lab's first paper is out in @Nature. We show that lipoprotein uptake protects tumors from ferroptosis by delivering the lipid antioxidant α-tocopherol. Surprisingly, tumors use sulfated glycosaminoglycans—not canonical receptors—to capture lipoproteins. nature.com/articles/s4158…
Congratulations @QingZhangLab and all!
Glad to share our latest research published in @NatureComms on identifying HLF as a critical regulator for lung metastasis in solid cancers. nature.com/articles/s4146…
Delighted to host @KidneyCancer model workshop @KCPUTSW
📢The KCA & @UTSWMedCenter invite researchers to participate in the *FIRST* RCC Animal Model Workshop this Sept 11-13! ‼️Apply by June 30, space limited‼️ Join us to drive research and accelerate therapeutics from lab to clinic. Email @salvolarosa: [email protected]
Congratulations to our one of a kind #AI #kidneycancer @KCPUTSW @UTSWcomps team with David Hein, Alana Christie, Bing Xie,@JVentoMD @jamieson_ai @PayalKapur5 on @npjDigitalMed #LLM paper rdcu.be/enlxw
Congratulations @CharlesJiangMD @KimrynRathmell
I spy @CharlesJiangMD @UTSWHemeOnc @utswcancer - congrats on your @ASCO @ConquerCancerFd #CDA! And congrats to all #YIA & #CDA recipients 🎉 @suzanneconzenmd @CarlosArteagaMD @ericpetersonMD
Congratulations!!!
Neat experience getting to speak about non-clear cell RCC subtypes after authoring a review with stellar UTSW mentors @QianJanieQin @TiansterZhang @PayalKapur5 @JBrugarolas @HHammersMD Review link: mdpi.com/2072-6694/17/9…
Congratulations @PayalKapur5 @BradLeibovichMD @MayoClinic @genentech @KCPUTSW @utswcancer @utswpath on identification of #RCC determinants of late mets academic.oup.com/jnci/article-a…
Congratulations to Satwik Rajaram @PayalKapur5 on @NatureComms report rdcu.be/eleeX of a DL AI tool to evaluate angiogenesis in #RCC @KCPUTSW @utswcancer @utswpath utsouthwestern.edu/newsroom/artic…
New leadership, bold opportunities: Jaehyuk Choi, M.D., Ph.D., joins UTSW as Director of the new Center for Cellular Therapies and Cancer Immunology, bringing groundbreaking research and a bold vision for advancing cancer treatment. Learn more: bit.ly/43bdgbP #CancerCare
Thank you @CarlosArteagaMD
Congratulations @JBrugarolas on your election to the Association of American Physicians. Great news for you, @KCPUTSW, and @UTSWCancer.
#ASCO and #AACR presidents hosting key #AACR25 #theranostics symposium featuring Dr de Vries who inspired our @KCPUTSW 40 #RCC #patients NCT04006522 soon to accrue
I am excited to share the latest paper from my lab where we leverage the selection bias of condensate-promoting oncofusions to uncover molecular rules governing condensate specificity and function. cell.com/cell/fulltext/….
Congratulations @bsabari and #team!
This work was only possible through a collaboration with @JBrugarolas @KCPUTSW and the hard work of a remarkable team of scientists at @UTSWScience led by @Heankel_ and @Prashan10011102.
Thank you @TiansterZhang for preparing the cases. Outstanding discussion. Congratulations to all the panelists. Chris would have liked it.
Fantastic #ChrisWood25 case discussion in advanced #RCC with steller panel @JBrugarolas @HHammersMD @utswcancer @KCPUTSW
Excellent session. Congratulations to the organizers.
Advanced renal session at UT Chris Wood Austin chaired by @TiansterZhang with @OncHahn discussing oligometastatic disease @QianJanieQin highlighting perioperative tx, @HHammersMD drug development and future directions and @JBrugarolas HIF2a targeting current status and resistance